{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:04:04Z","timestamp":1793963044719,"version":"4.8.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.esmoop.2025.105573","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:51:08Z","timestamp":1757011868000},"page":"105573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Toxicity and efficacy of antibody\u2013drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trials"],"prefix":"10.1016","volume":"10","author":[{"given":"R.","family":"Woodford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Almarzouq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Beygozlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cammarota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Grochot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.esmoop.2025.105573_bib1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105573_bib2","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1021\/acs.bioconjchem.5b00399","article-title":"Field guide to challenges and opportunities in antibody-drug conjugates for chemists","volume":"26","author":"Gordon","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105573_bib3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105573_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.esmoop.2025.105573_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","article-title":"Antibody-targeted drugs and drug resistance \u2013 challenges and solutions","volume":"18","author":"Shefet-Carasso","year":"2015","journal-title":"Drug Resist Updat"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105573_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105573_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","article-title":"Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire","volume":"17","author":"Haen","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105573_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105573_bib9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105573_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105573_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B (Methodol)"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105573_bib12","article-title":"Drug resistance and the role of combination chemotherapy in improving patient outcomes","volume":"2013","author":"Yardley","year":"2013","journal-title":"Int J Breast Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105573_bib13","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","article-title":"A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to Auristatin-based ADCs","volume":"21","author":"Yu","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105573_bib14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105573_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105573_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105573_bib17","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.7150\/thno.26370","article-title":"Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers-The first step towards an imaging warehouse","volume":"8","author":"Bensch","year":"2018","journal-title":"Theranostics"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105573_bib18","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105573_bib19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40259-017-0254-1","article-title":"Recent developments in ADC technology: preclinical studies signal future clinical trends","volume":"31","author":"Drake","year":"2017","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105573_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1699768","article-title":"Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human phase 1 studies","volume":"12","author":"Li","year":"2020","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105573_bib21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","article-title":"An FDA oncology analysis of antibody-drug conjugates","volume":"71","author":"Saber","year":"2015","journal-title":"Regul Toxicol Pharmacol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:19:22Z","timestamp":1759303162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2059702925014425"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105573","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity and efficacy of antibody\u2013drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trials","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105573"}}